Status:
COMPLETED
SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)
Lead Sponsor:
Desitin Arzneimittel GmbH
Conditions:
Parkinson's Disease
Eligibility:
All Genders
18+ years
Brief Summary
The objective of the Post Marketing Surveillance Study is to investigate the use of the non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy in patients with Mor...
Eligibility Criteria
Inclusion
- Male and female patients 18 years and older.
- Indication: Morbus Parkinson.
- Treatment with piribedil for the first time.
- Monotherapy with piribedil.
- Combination therapy with L-Dopa (from the beginning or secondary in combination with other antiparkinsonian drugs).
Exclusion
Key Trial Info
Start Date :
March 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2008
Estimated Enrollment :
750 Patients enrolled
Trial Details
Trial ID
NCT00727727
Start Date
March 1 2008
End Date
December 1 2008
Last Update
February 25 2009
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Practice for Neurology
Dresden, Germany, 01307
2
Medical Practice for Neurology
Wedel, Germany, 22880